tetano
Editor, Senior Moderator
J Infect Dis. 2012 May 21. [Epub ahead of print]
Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1 Infected Children and Youth.
Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; for the IMPAACT P1088 Team.
Source
From St. Jude Children's Research Hospital, Memphis TN.
Abstract
BackgroundSafety and immunogenicity of high-dose pandemic H1N1 (pH1N1) vaccination in perinatally HIV-1 infected children and youth is unknown.MethodsTwo 30 mcg doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin?), were administered 21-28 days apart to perinatally HIV-1 infected children and youth. Antibodies were measured by hemagglutination inhibition (HAI) at baseline, 21-28 days after first vaccination, 7-13 days after second, and 7 months after first.ResultsAmong the 155 participants, 54 were 4-8, 51 were 9-17, and 50 were 18-24 years old. After two doses of Fluvirin?, seroresponse (≥4 fold rise in HAI) was demonstrated in 79.6%, 84.8%, and 83% in each age group, respectively and seroprotection (HAI≥40) in 79.6%, 82.6%, and 85.1%, respectively. Of those lacking seroresponse (n=43) or seroprotection (n=37) after the first vaccination, 46.5% and 40.5% achieved seroresponse or seroprotection, respectively, after the second vaccination. Among participants who lacked seroprotection at entry, a "complete response" (both seroresponse and seroprotection) after first vaccination was associated with higher baseline log10 HAI titer and non-Hispanic ethnicity. No serious vaccine-related events occurred.ConclusionTwo doses of double-strength pH1N1 vaccine are safe and immunogenic and may provide improved protection against influenza in perinatally HIV-1 infected children and youth.
PMID:
22615311
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22615311
Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1 Infected Children and Youth.
Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; for the IMPAACT P1088 Team.
Source
From St. Jude Children's Research Hospital, Memphis TN.
Abstract
BackgroundSafety and immunogenicity of high-dose pandemic H1N1 (pH1N1) vaccination in perinatally HIV-1 infected children and youth is unknown.MethodsTwo 30 mcg doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin?), were administered 21-28 days apart to perinatally HIV-1 infected children and youth. Antibodies were measured by hemagglutination inhibition (HAI) at baseline, 21-28 days after first vaccination, 7-13 days after second, and 7 months after first.ResultsAmong the 155 participants, 54 were 4-8, 51 were 9-17, and 50 were 18-24 years old. After two doses of Fluvirin?, seroresponse (≥4 fold rise in HAI) was demonstrated in 79.6%, 84.8%, and 83% in each age group, respectively and seroprotection (HAI≥40) in 79.6%, 82.6%, and 85.1%, respectively. Of those lacking seroresponse (n=43) or seroprotection (n=37) after the first vaccination, 46.5% and 40.5% achieved seroresponse or seroprotection, respectively, after the second vaccination. Among participants who lacked seroprotection at entry, a "complete response" (both seroresponse and seroprotection) after first vaccination was associated with higher baseline log10 HAI titer and non-Hispanic ethnicity. No serious vaccine-related events occurred.ConclusionTwo doses of double-strength pH1N1 vaccine are safe and immunogenic and may provide improved protection against influenza in perinatally HIV-1 infected children and youth.
PMID:
22615311
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22615311